Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2009

01-10-2009 | Editorial

Androgens in rheumatoid arthritis: when are they effectors?

Author: Maurizio Cutolo

Published in: Arthritis Research & Therapy | Issue 5/2009

Login to get access

Abstract

Neither hormone receptor genes nor plasma androgens seem significantly altered in female subjects before they became affected by rheumatoid arthritis (RA) and, therefore, do not seem to play a role as risk factors for its development. However, serum testosterone levels are inversely correlated with RA activity and dehydro-epiandrosterone sulfate (DHEAS) plasma levels are inversely correlated with both disease duration and clinical severity in patients already affected by active RA. In particular, gonadal and adrenal androgens (that is, testosterone and DHEAS) are significantly decreased in inflamed synovial tissue/fluids during active disease as a consequence of the inflammatory reaction, which supports a pro-inflammatory milieu in RA joints. Recently, male gender has been found to be a major predictor of remission in early RA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Karlson EW, Chibnik LB, McGrath M, Chang SC, Keenan BT, Costenbader KH, Fraser PA, Tworoger S, Hankinson SE, Lee IM, Buring J, De Vivo I: A prospective study of androgen levels, hormone related genes and risk of rheumatoid arthritis. Arthritis Res Ther. 2009, 11: R97-10.1186/ar2742.PubMedCentralCrossRefPubMed Karlson EW, Chibnik LB, McGrath M, Chang SC, Keenan BT, Costenbader KH, Fraser PA, Tworoger S, Hankinson SE, Lee IM, Buring J, De Vivo I: A prospective study of androgen levels, hormone related genes and risk of rheumatoid arthritis. Arthritis Res Ther. 2009, 11: R97-10.1186/ar2742.PubMedCentralCrossRefPubMed
2.
go back to reference Cutolo M, Straub RH: Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther. 2009, 11: 218-10.1186/ar2630.PubMedCentralCrossRefPubMed Cutolo M, Straub RH: Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther. 2009, 11: 218-10.1186/ar2630.PubMedCentralCrossRefPubMed
3.
go back to reference Cutolo M, Straub RH, Bijlsma JW: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol. 2007, 3: 627-634. 10.1038/ncprheum0601.CrossRefPubMed Cutolo M, Straub RH, Bijlsma JW: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol. 2007, 3: 627-634. 10.1038/ncprheum0601.CrossRefPubMed
4.
go back to reference Gordon D, Beastall GH, Thomson JA, Sturrock RD: Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. Br J Rheumatol. 1988, 27: 440-444. 10.1093/rheumatology/27.6.440.CrossRefPubMed Gordon D, Beastall GH, Thomson JA, Sturrock RD: Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. Br J Rheumatol. 1988, 27: 440-444. 10.1093/rheumatology/27.6.440.CrossRefPubMed
5.
go back to reference Forslind K, Hafström I, Ahlmén M, Svensson B, BARFOT Study Group: Sex: a major predictor of remission in early rheumatoid arthritis?. Ann Rheum Dis. 2007, 66: 46-52. 10.1136/ard.2006.056937.PubMedCentralCrossRefPubMed Forslind K, Hafström I, Ahlmén M, Svensson B, BARFOT Study Group: Sex: a major predictor of remission in early rheumatoid arthritis?. Ann Rheum Dis. 2007, 66: 46-52. 10.1136/ard.2006.056937.PubMedCentralCrossRefPubMed
6.
go back to reference Straub RH, Härle P, Sarzi-Puttini P, Cutolo M: Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum. 2006, 54: 2039-2046. 10.1002/art.21946.CrossRefPubMed Straub RH, Härle P, Sarzi-Puttini P, Cutolo M: Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum. 2006, 54: 2039-2046. 10.1002/art.21946.CrossRefPubMed
7.
go back to reference Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH: Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006, 1069: 391-400. 10.1196/annals.1351.037.CrossRefPubMed Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH: Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006, 1069: 391-400. 10.1196/annals.1351.037.CrossRefPubMed
8.
go back to reference Capellino S, Montagna P, Villaggio B, Soldano S, Straub RH, Cutolo M: Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol. 2008, 26: 903-909.PubMed Capellino S, Montagna P, Villaggio B, Soldano S, Straub RH, Cutolo M: Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol. 2008, 26: 903-909.PubMed
9.
go back to reference Komi J, Möttönen M, Luukkainen R, Lassila O: Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells. Rheumatology (Oxford). 2001, 40: 185-191. 10.1093/rheumatology/40.2.185.CrossRef Komi J, Möttönen M, Luukkainen R, Lassila O: Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells. Rheumatology (Oxford). 2001, 40: 185-191. 10.1093/rheumatology/40.2.185.CrossRef
10.
go back to reference Cutolo M, Balleari E, Giusti M, Intra E, Accardo S: Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34: 1-5. 10.1002/art.1780340102.CrossRefPubMed Cutolo M, Balleari E, Giusti M, Intra E, Accardo S: Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34: 1-5. 10.1002/art.1780340102.CrossRefPubMed
11.
go back to reference Cutolo M, Straub RH: Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation. 2006, 13: 277-282. 10.1159/000104855.CrossRefPubMed Cutolo M, Straub RH: Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation. 2006, 13: 277-282. 10.1159/000104855.CrossRefPubMed
12.
go back to reference Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B: Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J Rheumatol. 2007, 34: 1451-1458.PubMed Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B: Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J Rheumatol. 2007, 34: 1451-1458.PubMed
Metadata
Title
Androgens in rheumatoid arthritis: when are they effectors?
Author
Maurizio Cutolo
Publication date
01-10-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2804

Other articles of this Issue 5/2009

Arthritis Research & Therapy 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.